You have full access to this article via your institution. Currently, the patient is 4.5 years old with a Hb of 13 g/dL (Hb A, 85%; Hb A 2, 2.5%). She has not required blood transfusion for almost 2.5 ...

All four parent studies are complete, and all patients have transitioned to a long-term follow-up study (LTF-303) SOMERVILLE, Mass.--(BUSINESS WIRE)--Updated data from bluebird bio inc.’s (NASDAQ: ...

A novel microfluidic device to model the human kidney The group targeting higher hemoglobin values experienced less decline in graft function. NEW ORLEANS—Kidney transplant recipients with ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene ...